Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.
Target Price
The average target price of 9688.HK is 37 and suggests 154% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell